NAOV Profile
NanoVibronix, Inc., headquartered in Elmsford, New York, operates through its subsidiary, NanoVibronix Ltd., specializing in the development and commercialization of noninvasive biological response-activating devices. The company’s innovative technology focuses on biofilm prevention, wound healing, and pain therapy, offering a range of ultrasound-based solutions designed to address various medical needs.
NanoVibronix's flagship product, UroShield, utilizes ultrasound technology to prevent bacterial colonization and biofilm formation in urinary catheters. This device aims to enhance the efficacy of antibiotics while reducing pain and discomfort associated with catheter use. The company's PainShield product employs therapeutic ultrasound in a patch format to treat pain, muscle spasms, and joint contractures. This noninvasive approach provides a targeted treatment for chronic pain conditions.
The WoundShield device, another key offering, is a patch-based therapeutic ultrasound tool designed to accelerate tissue regeneration and facilitate wound healing. By promoting enhanced cellular activity, WoundShield supports the healing process in various types of wounds. NanoVibronix markets its products both directly to patients and through distributor agreements, with a presence in the United States, Israel, Europe, India, and other international markets.
Founded in 2003, NanoVibronix is committed to advancing noninvasive therapeutic technologies that improve patient outcomes and enhance the quality of medical treatments. Its product portfolio underscores the company’s focus on addressing critical healthcare challenges through innovative solutions, leveraging its expertise in ultrasound technology to offer effective and practical solutions for pain management, infection prevention, and wound care.
|
